Shamburg News · 8-K filed Nov 12, 2026, 8:05 AM EST

Prime Medicine Prices $134.7 Million Underwritten Public Offering of Common Stock

PRME · Prime Medicine, Inc.

  • Financing
  • Material agreement
  • Materiality: high

On November 10, 2026, Prime Medicine, Inc. entered into an Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC and Goldman Sachs & Co. LLC for an underwritten public offering of 35,714,286 shares of common stock at $3.50 per share, with an option for the underwriters to purchase up to an additional 5,357,142 shares. The Company estimates net proceeds of approximately $134.7 million, including full exercise of the option, to be used primarily for its Wilson disease and alpha-1 antitrypsin deficiency programs and other R&D, with the remainder for working capital and general corporate purposes. The offering is expected to close on or about November 12, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 9.01, accession 0001628280-26-073131.

Written from the filing by Shamburg Markets. Figures are as reported by the company.